Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAggressive LymphomasIndolent LymphomasTransplantationDiseaseHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaStem Cell Transplantation, AutologousSubgroupICD10C81.-C82.-C82.7C82.9C83.0C83.1C83.3C84.6C88.0-Z94.80MeSHLymphoma, FollicularLymphoma, Mantle-CellWaldenstrom MacroglobulinemiaSequenceChemotherapyChemo-substanceBendamustineCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabThiotepaChemo-substanceBendamustineCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabThiotepaChemo-substanceBendamustineCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabThiotepaChemo-substanceBendamustineCarmustineCytarabineDexamethasoneEtoposideMelphalanRituximabThiotepaNo. Substances46 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimNo. Substances46Protocol classificationTherapy classificationalternativecurrent standardIntensityHigh dose myeloablativeStandard doseTherapy indicationRelapse therapyseveral possibleTherapy phaseconditioningSalvageTherapy intentioncurativeRisksDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHepatotoxicityInfectionsMucositisOral MucositisPyrexia only studiesPublicationAuthorCaballero MDDulery RKirschey SVisani GDiseaseNHL, HL, Rezidiv, fehlende Remission nach kurativer Chemotherapierefraktäres oder rezidivierendes NHL oder HL, Rituximab Vortherapierezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2rezidiviertes Hodgkin und Non-Hodgkin Lymphom, erste StammzelltransplantationOriginDepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Hematology, Hospital Universitario Salamanca, SpanienHematology and Stem Cell Transplant Center, Marche Nord Hospital, Pesaro, ItalyIRCCS Casa Sllievo della Sofferenza, San Giovanni Rotondo, ItalienProtocols in Revision 4 protocols foundProtocols under revision.BEAM - Carmustine 300 / Etoposide 200 / Cytarabine 200 / Melphalan 140, prior to autologous Stem Cell Transplantation, Autologous (PID280)BeEAM - Bendamustine 100 / Etoposide 200 / Cytarabine 200 / Melphalan 140, prior to autologous Stem Cell Transplantation (PID879)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006)TEAM - Thiotepa 5 / Etoposide 100 / Cytarabine 200 / Melphalan 200, before autologous Stem Cell Transplantation (PID406)